论文部分内容阅读
目的探讨血药浓度监测在甲氨蝶呤治疗急性淋巴细胞性白血病患者中的意义。方法采用均相酶扩大免疫法(EMIT)对使用甲氨蝶呤后24 h、48 h、72 h的血药浓度进行监测。结果对20例患者进行43次的甲氨蝶呤浓度测定,其中仅有1例患者出现了甲氨蝶呤排泄延迟的情况。结论在临床治疗急性淋巴细胞性白血病中,进行甲氨蝶呤血药浓度监测是必要的,同时要时刻观察患者用药时出现的不良反应,并及时进行相应的处理。
Objective To investigate the significance of plasma concentration monitoring in the treatment of acute lymphoblastic leukemia with methotrexate. Methods Plasma concentrations of 24, 48, and 72 h after methotrexate were monitored using homogeneous enzyme immunoassay (EMIT). Results Methotrexate concentrations were measured 43 times in 20 patients, and only 1 patient had methotrexate excretion delayed. Conclusion In the clinical treatment of acute lymphoblastic leukemia, it is necessary to monitor the plasma concentration of methotrexate. At the same time, we must observe the adverse reactions that occur when the patient is taking the drug, and perform corresponding treatment in time.